Emcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention and treatment. This royalty-free agreement focuses on increasing access to the drug in 120 countries,

Gilead Sciences has announced the signing of voluntary licencing agreements with six generic pharmaceutical manufacturers to facilitate access to lenacapavir, a potential human immunodeficiency virus (HIV) prevention drug,

Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries.

Indian pharmaceutical companies are set to produce generic versions of lenacapavir, an HIV prevention drug, under agreements with US-based Gilead Sciences to distribute it in 120 resource-limited countries.